Brachytherapy boost in anal canal cancer – A GEC ESTRO PDR task force meta-analysis
Annede P, Ferre M, Kirisits C, Pieters BR, Schmid M, Strnad V, Westerveld H, Chargari C (2023)
Publication Type: Journal article
Publication year: 2023
Journal
Book Volume: 39
Article Number: 100589
DOI: 10.1016/j.ctro.2023.100589
Abstract
Purpose: A meta-analysis is presented comparing clinical outcomes and toxicities between high dose rate (HDR) and pulsed dose rate (PDR) brachytherapy (BT) for anal cancer. Methods and material: Retrospective or prospective clinical trials were identified on electronical databases. Data were collected per Preferred Reporting Items for Systematic Reviews and meta-Analyses guidelines. Pooled effect size for HDR and PDR BT were compared using subgroup analyses. Results: Nine retrospective studies with a total of 481 patients treated were included of which 219 with HDR and 262 with PDR. Significant differences were observed between the two groups for baseline characteristics and treatment. The cumulative proportion of stage T3-T4 was lower in the HDR group, 0.15 [95 % confidence interval (CI) 0.07–0.29] vs 0.27 [95 %CI 0.09–0.57] in the LDR group, p < 0.001. Lower BT doses (in equivalent 2-Gy fraction dose) were given for patients in the HDR group, 11.9 Gy [95 %CI 8.2–15.5] vs 19.5 Gy [95 %CI 15.0–24.0] in the PDR group, p < 0.001. No significant differences were found for clinical outcomes or toxicities. The pooled effect size of the overall survival at 5 years for HDR and PDR was respectively 0.82 [95 %CI 0.70–0.94] and 0.82 [95 %CI 0.73–0.91], p > 0.99. The 5 years local control was 0.86 [95 % confidence interval (CI) 0.81–0.91] and 0.83 [95 %CI 0.77–0.89], p = 0.62. Cumulative toxicity-related colostomy proportion was 0.04 [95 %CI 0.02–0.09] and 0.03 [95 %CI 0.02–0.07], p = 0.85. Conclusion: Both modalities provided a good profile of tolerance and are effective organ conservative strategies for patients with anal canal cancer. In parallel with ongoing developments to better determine the optimal fractionation and dose for HDR-BT treatments, especially in large tumors, PDR BT still has a crucial role for dose escalation strategy in advanced cases.
Authors with CRIS profile
Involved external institutions
Université Paris-Saclay
France (FR)
Institute Paoli-Calmettes
France (FR)
Medizinische Universität Wien
Austria (AT)
Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Assistance Publique-Hôpitaux de Paris (AP-HP)
France (FR)
France (FR)
Institute Paoli-Calmettes
France (FR)
Medizinische Universität Wien
Austria (AT)
Amsterdam University Medical Centers (Amsterdam UMC) / Amsterdam Universitair Medische Centra
Netherlands (NL)
Erasmus University Medical Center (MC)
Netherlands (NL)
Assistance Publique-Hôpitaux de Paris (AP-HP)
France (FR)
How to cite
APA:
Annede, P., Ferre, M., Kirisits, C., Pieters, B.R., Schmid, M., Strnad, V.,... Chargari, C. (2023). Brachytherapy boost in anal canal cancer – A GEC ESTRO PDR task force meta-analysis. Clinical and Translational Radiation Oncology, 39. https://dx.doi.org/10.1016/j.ctro.2023.100589
MLA:
Annede, Pierre, et al. "Brachytherapy boost in anal canal cancer – A GEC ESTRO PDR task force meta-analysis." Clinical and Translational Radiation Oncology 39 (2023).
BibTeX: Download